Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL334377 | 0.86 | NQO1 (0.44) | ALDH1A1MEN1KMT2A | |
| SCHEMBL335816 | 0.82 | AOC3 (0.46) | AOC3TAAR1ACHESLC6A4 | |
| SCHEMBL334526 | 0.82 | AOC3 (0.46) | AOC3TAAR1ACHESLC6A4 | |
| SCHEMBL335352 | 0.81 | ALOX5 (0.42) | ALOX5TAAR1CYP1A2ACHEMAOA | |
| SCHEMBL334958 | 0.80 | ALOX5 (0.44) | ALOX5ALDH1A1TAAR1CYP2D6MAOA | |
| SCHEMBL335097 | 0.80 | ADRB2 (0.42) | ALDH1A1AOC3TAAR1CYP1A2CYP2D6 | |
| SCHEMBL335079 | 0.80 | TAAR1 (0.42) | ALOX5ALDH1A1TAAR1 | |
| SCHEMBL334729 | 0.80 | ROCK1 (0.39) | AOC3TAAR1MAOAMAOBMEN1 | |
| SCHEMBL10779533 | 0.80 | AOC3 (0.45) | ALOX5ALDH1A1AOC3CYP1A2CYP2D6 | |
| SCHEMBL335260 | 0.80 | HRH1 (0.45) | ALOX5AOC3TAAR1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | ALOX5 2387/4885ALDH1A1 1939/4885AOC3 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.